MTAA
PHIL
Market cap738mUSD
Jul 30, Last price
22.30EUR
1D
-0.89%
1Q
2.29%
IPO
43.87%
Name
Philogen SpA
Chart & Performance
P/E
14.26
P/S
8.32
EPS
1.56
Div Yield, %
—
Shrs. gr., 5y
6.62%
Rev. gr., 5y
43.84%
Revenues
78m
+235.72%
Net income
45m
P
CFO
41m
P
Profile
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 77,653 235.72% | 23,130 -2.46% | 23,713 850.04% | |||||
Cost of revenue | 36,034 | 38,292 | 29,315 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 41,619 | (15,162) | (5,602) | |||||
NOPBT Margin | 53.60% | |||||||
Operating Taxes | 4,916 | (20) | 1,017 | |||||
Tax Rate | 11.81% | |||||||
NOPAT | 36,703 | (15,142) | (6,619) | |||||
Net income | 45,292 -835.14% | (6,161) 14.60% | (5,376) -65.81% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (27) | (2,379) | (1,924) | |||||
BB yield | 0.00% | 0.32% | ||||||
| Debt | ||||||||
Debt current | 1,889 | 871 | ||||||
Long-term debt | 25,126 | 22,911 | ||||||
Deferred revenue | 1,507 | 1,962 | ||||||
Other long-term liabilities | 2,683 | 3,128 | 3,948 | |||||
Net debt | (48,329) | (65,405) | ||||||
| Cash flow | ||||||||
Cash from operating activities | 40,842 | (3,253) | (4,939) | |||||
CAPEX | (2,167) | (5,545) | (4,211) | |||||
Cash from investing activities | (22,283) | 159 | 24,197 | |||||
Cash from financing activities | (3,779) | (4,173) | (3,782) | |||||
FCF | 37,097 | (17,929) | (11,140) | |||||
| Balance | ||||||||
Cash | 75,344 | 86,200 | ||||||
Long term investments | 1 | 2,987 | ||||||
Excess cash | 74,188 | 88,001 | ||||||
Stockholders' equity | 138,657 | (6,586) | (6,164) | |||||
Invested Capital | 141,340 | 113,910 | 121,217 | |||||
ROIC | 28.76% | |||||||
ROCE | 29.45% | |||||||
| EV | ||||||||
Common stock shares outstanding | 40,290 | 40,247 | 40,415 | |||||
Price | 19.50 5.41% | 18.50 | ||||||
Market cap | 785,647 5.52% | 744,578 | ||||||
EV | 785,647 | 696,249 | ||||||
EBITDA | 45,506 | (11,521) | (2,820) | |||||
EV/EBITDA | 17.26 | |||||||
Interest | 547 | 406 | ||||||
Interest/NOPBT | ||||||||